Verve Therapeutics, Inc. engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
Market Cap | 1.842 Billion | Shares Outstanding | 48.665 Million | Avg 30-day Volume | 1.446 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -6.66 |
Price to Revenue | 0.0 | Debt to Equity | 0.0031 | EBITDA | -120.769 Million |
Price to Book Value | 3.0908 | Operating Margin | 0.0 | Enterprise Value | 623.265 Million |
Current Ratio | 11.554 | EPS Growth | 0 | Quick Ratio | 11.358 |
1 Yr BETA | 2.2514 | 52-week High/Low | 78.0 / 10.7 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -120.2909 | Altman Z-Score | 18.2949 | Free Cash Flow to Firm | 0 |
Earnings Report | 2022-11-10 |
Please sign in first
none
385 Thousand total shares from 10 transactions
130 Thousand total shares from 4 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
KATHIRESAN SEKAR CHIEF EXECUTIVE OFFICER |
|
807,258 | 2022-08-10 | 8 |
|
0 | 2022-08-08 | 2 | |
|
570,729 | 2022-07-26 | 9 | |
BELLINGER ANDREW CSO & CMO |
|
8,228 | 2022-07-20 | 5 |
|
15,500 | 2022-06-09 | 4 | |
|
15,500 | 2022-06-09 | 1 | |
|
15,500 | 2022-06-09 | 1 | |
|
0 | 2022-06-09 | 2 | |
|
15,500 | 2022-06-09 | 1 | |
|
15,500 | 2022-06-09 | 1 | |
ASHE ANDREW D. SEE REMARKS |
|
125,000 | 2022-02-11 | 2 |
DORVAL ALLISON CHIEF FINANCIAL OFFICER |
|
60,000 | 2022-02-11 | 3 |
ARCH VENTURE FUND X OVERAGE, L.P. |
|
No longer subject to file | 2021-06-21 | 0 |
|
No longer subject to file | 2021-06-21 | 0 | |
|
No longer subject to file | 2021-06-21 | 0 | |
|
No longer subject to file | 2021-06-21 | 0 | |
CORMORANT ASSET MANAGEMENT, LP |
|
No longer subject to file | 2021-06-21 | 0 |
ROCK SPRINGS CAPITAL MANAGEMENT LP |
|
No longer subject to file | 2021-06-21 | 0 |
|
6,320,905 | 2021-06-21 | 0 | |
|
No longer subject to file | 2021-06-21 | 0 | |
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P. |
|
No longer subject to file | 2021-06-21 | 0 |
|
No longer subject to file | 2021-06-21 | 0 | |
|
No longer subject to file | 2021-06-21 | 0 | |
|
4,472,509 | 2021-06-21 | 0 | |
|
No longer subject to file | 2021-06-21 | 0 | |
BEAUDOIN MARGARET VICE PRESIDENT, FINANCE |
|
11,799 | 2021-06-17 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-08-11 17:00:28 -0400 | 2022-08-10 | M | 50,000 | d | 167,425 | direct | |||||||||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-08-11 17:00:28 -0400 | 2022-08-10 | S | 50,000 | $29.90 | d | 317,839 | direct | yes | 6.3782 | 6.3782 | 2 | 0.0 | 1 | ||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-08-11 17:00:28 -0400 | 2022-08-10 | M | 50,000 | $1.39 | a | 367,839 | direct | 6.3782 | 6.3782 | 2 | 0.0 | 1 | |||
2022-08-09 17:05:20 -0400 | 2022-08-08 | A | 31,000 | a | 31,000 | direct | ||||||||||
2022-07-22 17:00:35 -0400 | 2022-07-20 | M | 20,000 | d | 1,599 | direct | ||||||||||
2022-07-22 17:00:35 -0400 | 2022-07-20 | S | 20,000 | $34.90 | d | 6,629 | direct | yes | -4.2646 | -24.1101 | 0.0 | 1 | -24.1101 | 6 | ||
2022-07-22 17:00:35 -0400 | 2022-07-20 | M | 20,000 | $1.39 | a | 26,629 | direct | -4.2646 | -24.1101 | 0.0 | 1 | -24.1101 | 6 | |||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-07-21 17:00:32 -0400 | 2022-07-19 | M | 50,000 | d | 217,425 | direct | |||||||||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-07-21 17:00:32 -0400 | 2022-07-19 | S | 50,000 | $29.90 | d | 317,839 | direct | yes | -2.7115 | -19.5688 | 0.0 | 1 | -19.5688 | 6 | |
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-07-21 17:00:32 -0400 | 2022-07-19 | M | 50,000 | $1.39 | a | 367,839 | direct | -2.7115 | -19.5688 | 0.0 | 1 | -19.5688 | 6 | ||
2022-07-15 17:00:23 -0400 | 2022-07-13 | M | 10,000 | $1.48 | a | 16,629 | direct | 22.729 | 13.1889 | 36.488 | 3 | 0.0 | 1 | |||
2022-07-15 17:00:23 -0400 | 2022-07-13 | M | 10,000 | d | 136,995 | direct | ||||||||||
2022-07-15 17:00:23 -0400 | 2022-07-13 | S | 10,000 | $24.90 | d | 6,629 | direct | yes | 22.729 | 13.1889 | 36.488 | 3 | 0.0 | 1 | ||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER sekar kathiresan 2022 annuity trust |
2022-07-15 17:00:27 -0400 | 2022-07-12 | G | 160,000 | a | 300,000 | indirect | |||||||||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER sekar kathiresan 2022 annuity trust |
2022-07-15 17:00:27 -0400 | 2022-07-12 | G | 140,000 | a | 140,000 | indirect | |||||||||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-07-15 17:00:27 -0400 | 2022-07-12 | G | 160,000 | d | 445,308 | direct | |||||||||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-07-15 17:00:27 -0400 | 2022-07-12 | G | 140,000 | d | 291,988 | direct | |||||||||
FMR LLC - > 10% Owner SEE REMARK 1 f-prime capital partners healthcare fund v lp |
2022-07-14 17:24:23 -0400 | 2022-07-12 | S | 63,000 | $22.04 | d | 570,729 | indirect | 10.9658 | 29.1016 | 51.4551 | 4 | 0.0 | 1 | ||
FMR LLC - > 10% Owner SEE REMARK 1 f-prime capital partners healthcare fund v lp |
2022-07-14 17:24:23 -0400 | 2022-07-12 | S | 100,000 | $19.98 | d | 633,729 | indirect | 10.9658 | 29.1016 | 51.4551 | 4 | 0.0 | 1 | ||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER kathiresan family 2021 irrevocable trust |
2022-07-15 17:00:27 -0400 | 2022-07-07 | G | 160,000 | a | 240,997 | indirect | 22.729 | 13.1889 | 36.488 | 3 | 0.0 | 1 | |||
KATHIRESAN SEKAR - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-07-15 17:00:27 -0400 | 2022-07-07 | G | 160,000 | d | 317,839 | direct | 22.729 | 13.1889 | 36.488 | 3 | 0.0 | 1 | |||
FMR LLC - > 10% Owner SEE REMARK 1 f-prime capital partners healthcare fund v lp |
2022-07-06 12:56:20 -0400 | 2022-07-01 | S | 38,775 | $15.66 | d | 773,729 | indirect | 12.7914 | 43.0927 | 43.0927 | 6 | 0.0 | 1 | ||
FMR LLC - > 10% Owner SEE REMARK 1 f-prime capital partners healthcare fund v lp |
2022-07-01 14:54:44 -0400 | 2022-06-30 | S | 18,810 | $15.21 | d | 772,504 | indirect | 2.5592 | 31.0301 | 142.2265 | 142.2265 | 31 | 0.0 | 1 | |
FMR LLC - > 10% Owner SEE REMARK 1 f-prime capital partners healthcare fund v lp |
2022-07-01 14:54:44 -0400 | 2022-06-29 | S | 4,047 | $15.50 | d | 821,676 | indirect | 2.5592 | 31.0301 | 142.2265 | 142.2265 | 31 | 0.0 | 1 | |
FMR LLC - > 10% Owner SEE REMARK 1 f-prime capital partners healthcare fund v lp |
2022-07-01 14:54:44 -0400 | 2022-06-29 | S | 30,362 | $15.60 | d | 791,314 | indirect | 2.5592 | 31.0301 | 142.2265 | 142.2265 | 31 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
VERVE THERAPEUTICS INC VERV | 2022-08-16 22:15:05 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 21:45:03 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 21:15:03 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 20:45:05 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 20:15:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 19:45:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 19:15:05 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 18:45:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 18:15:05 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 17:45:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 17:15:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 16:45:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 16:15:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 15:45:04 UTC | 1.2108 | 1.1092 | 1200000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 15:15:03 UTC | 1.2108 | 1.1092 | 1100000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 14:45:03 UTC | 1.2108 | 1.1092 | 1000000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 14:15:04 UTC | 1.2108 | 1.1092 | 1000000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 13:45:05 UTC | 1.2121 | 1.1079 | 1000000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 13:15:04 UTC | 1.2121 | 1.1079 | 1000000 |
VERVE THERAPEUTICS INC VERV | 2022-08-16 12:45:03 UTC | 1.2121 | 1.1079 | 1000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | VERV | -1800.0 shares, $-41076.0 | 2022-03-31 | N-PORT |
Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund | VERV | -3630.0 shares, $-54159.6 | 2022-04-30 | N-PORT |
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund | VERV | -592.0 shares, $-8832.64 | 2022-04-30 | N-PORT |
RBB Fund, Inc.- Boston Partners Long/Short Research Fund | VERV | -25432.0 shares, $-385549.12 | 2022-05-31 | N-PORT |
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | VERV | -4948.0 shares, $-112913.36 | 2022-03-31 | N-PORT |